Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Is rate of return pricing a useful approach when value-based pricing is not appropriate?

Drummond M, Towse A.

Eur J Health Econ. 2019 Feb 15. doi: 10.1007/s10198-019-01032-7. [Epub ahead of print] No abstract available.

PMID:
30771033
2.

A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions.

Pearson SD, Dreitlein WB, Towse A, Hampson G, Henshall C.

J Comp Eff Res. 2018 Dec;7(12):1145-1152. doi: 10.2217/cer-2018-0059. Epub 2018 Nov 14.

3.

Real-world evidence for coverage decisions: opportunities and challenges.

Hampson G, Towse A, Dreitlein WB, Henshall C, Pearson SD.

J Comp Eff Res. 2018 Dec;7(12):1133-1143. doi: 10.2217/cer-2018-0066. Epub 2018 Nov 9.

4.

Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.

J├Ânsson B, Hampson G, Michaels J, Towse A, von der Schulenburg JG, Wong O.

Eur J Health Econ. 2019 Apr;20(3):427-438. doi: 10.1007/s10198-018-1007-x. Epub 2018 Sep 18.

5.

Paying for Cures: Perspectives on Solutions to the "Affordability Issue".

Schaffer SK, Messner D, Mestre-Ferrandiz J, Tambor E, Towse A.

Value Health. 2018 Mar;21(3):276-279. doi: 10.1016/j.jval.2017.12.013. Review.

6.

Affordability of New Technologies: The Next Frontier.

Towse A, Mauskopf JA.

Value Health. 2018 Mar;21(3):249-251. doi: 10.1016/j.jval.2018.01.011. Epub 2018 Feb 19. No abstract available.

7.

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Garrison LP Jr, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC.

Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.

8.

Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].

Phelps CE, Lakdawalla DN, Basu A, Drummond MF, Towse A, Danzon PM.

Value Health. 2018 Feb;21(2):146-154. doi: 10.1016/j.jval.2017.12.010.

9.

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Danzon PM, Drummond MF, Towse A, Pauly MV.

Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.

10.

Gene therapy: evidence, value and affordability in the US health care system.

Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C.

J Comp Eff Res. 2018 Jan;7(1):15-28. doi: 10.2217/cer-2017-0068. Epub 2017 Nov 16. Review.

11.

What do pharmaceuticals really cost in the long run?

Lakdawalla D, MacEwan JP, Dubois R, Westrich K, Berdud M, Towse A.

Am J Manag Care. 2017 Aug;23(8):488-493.

12.

Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.

Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH.

Health Policy. 2017 Oct;121(10):1025-1030. doi: 10.1016/j.healthpol.2017.07.011. Epub 2017 Aug 5.

13.

Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics.

Garrison LP, Towse A.

J Pers Med. 2017 Sep 4;7(3). pii: E10. doi: 10.3390/jpm7030010. Review.

14.

Indication-specific pricing of pharmaceuticals in the US healthcare system.

Pearson SD, Dreitlein WB, Henshall C, Towse A.

J Comp Eff Res. 2017 Jul;6(5):397-404. doi: 10.2217/cer-2017-0018. Epub 2017 Jul 12.

15.

ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA.

Hampson G, Henshall C, Towse A.

Int J Technol Assess Health Care. 2017 Jan;33(2):315-322. doi: 10.1017/S0266462317000496. Epub 2017 May 30.

PMID:
28554337
16.

Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis.

Garrison LP Jr, Kamal-Bahl S, Towse A.

Value Health. 2017 Feb;20(2):213-216. doi: 10.1016/j.jval.2016.12.005.

17.

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Malone DC, Berg NS, Claxton K, Garrison LP Jr, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC.

J Clin Oncol. 2016 Aug 20;34(24):2936-7. doi: 10.1200/JCO.2015.64.4328. Epub 2016 Jun 13. No abstract available.

18.

IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDY.

Garau M, Shah KK, Sharma P, Towse A.

Int J Technol Assess Health Care. 2015;31(6):449-56. doi: 10.1017/S0266462315000616. Epub 2016 Feb 12.

19.

UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH.

Towse A, Jonsson B, McGrath C, Mason A, Puig-Peiro R, Mestre-Ferrandiz J, Pistollato M, Devlin N.

Int J Technol Assess Health Care. 2015;31(6):363-70. doi: 10.1017/S0266462315000719. Epub 2016 Feb 3.

20.

Biosimilars: How Can Payers Get Long-Term Savings?

Mestre-Ferrandiz J, Towse A, Berdud M.

Pharmacoeconomics. 2016 Jun;34(6):609-16. doi: 10.1007/s40273-015-0380-x.

Supplemental Content

Loading ...
Support Center